Literature DB >> 31646077

Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy.

Sara Verdura1,2, Elisabet Cuyàs1,2, Begoña Martin-Castillo3, Javier A Menendez1,2.   

Abstract

The development of a single immuno-metabolic adjuvant capable of modulating, in the appropriate direction and intensity, the complex antagonistic and symbiotic interplays between tumor cells, immune cells, and the gut microbiota may appear pharmacologically implausible. Metformin might help solve this conundrum and beneficially impact the state of cancer-immune system interactions.
© 2019 The Author(s). Published with license by Taylor & Francis Group, LLC.

Entities:  

Keywords:  Metformin; T-cells; immune checkpoints; immunotherapy

Year:  2019        PMID： 31646077      PMCID： PMC6791450          DOI： 10.1080/2162402X.2019.1633235

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  116 in total

1.  Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer.

Authors:  Kristin J Lastwika; Willie Wilson; Qing Kay Li; Jeffrey Norris; Haiying Xu; Sharon R Ghazarian; Hiroshi Kitagawa; Shigeru Kawabata; Janis M Taube; Sheng Yao; Linda N Liu; Joell J Gills; Phillip A Dennis
Journal:  Cancer Res       Date:  2015-12-04       Impact factor: 12.701

Review 2.  Metabolic Barriers to T Cell Function in Tumors.

Authors:  Ayaka Sugiura; Jeffrey C Rathmell
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

Review 3.  T cell exhaustion.

Authors:  E John Wherry
Journal:  Nat Immunol       Date:  2011-06       Impact factor: 25.606

Review 4.  Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis.

Authors:  Andrea Decensi; Matteo Puntoni; Pamela Goodwin; Massimiliano Cazzaniga; Alessandra Gennari; Bernardo Bonanni; Sara Gandini
Journal:  Cancer Prev Res (Phila)       Date:  2010-10-12

Review 5.  Navigating metabolic pathways to enhance antitumour immunity and immunotherapy.

Authors:  Xiaoyun Li; Mathias Wenes; Pedro Romero; Stanley Ching-Cheng Huang; Sarah-Maria Fendt; Ping-Chih Ho
Journal:  Nat Rev Clin Oncol       Date:  2019-07       Impact factor: 66.675

6.  Metformin Suppresses Tumor Progression by Inactivating Stromal Fibroblasts in Ovarian Cancer.

Authors:  Sen Xu; Zongyuan Yang; Ping Jin; Xin Yang; Xiaoting Li; Xiao Wei; Ya Wang; Sixiang Long; Taoran Zhang; Gang Chen; Chaoyang Sun; Ding Ma; Qinglei Gao
Journal:  Mol Cancer Ther       Date:  2018-03-15       Impact factor: 6.261

7.  Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1).

Authors:  Michal Marzec; Qian Zhang; Ami Goradia; Puthiyaveettil N Raghunath; Xiaobin Liu; Michele Paessler; Hong Yi Wang; Maria Wysocka; Mangeng Cheng; Bruce A Ruggeri; Mariusz A Wasik
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-16       Impact factor: 11.205

8.  Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients.

Authors:  J Rogado; J M Sánchez-Torres; N Romero-Laorden; A I Ballesteros; V Pacheco-Barcia; A Ramos-Leví; R Arranz; A Lorenzo; P Gullón; O Donnay; M Adrados; P Costas; J Aspa; A Alfranca; R Mondéjar; R Colomer
Journal:  Eur J Cancer       Date:  2019-01-22       Impact factor: 9.162

9.  Metformin regulates global DNA methylation via mitochondrial one-carbon metabolism.

Authors:  E Cuyàs; S Fernández-Arroyo; S Verdura; R Á-F García; J Stursa; L Werner; E Blanco-González; M Montes-Bayón; J Joven; B Viollet; J Neuzil; J A Menendez
Journal:  Oncogene       Date:  2017-10-23       Impact factor: 9.867

10.  Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs.

Authors:  Bruna Corominas-Faja; Rosa Quirantes-Piné; Cristina Oliveras-Ferraros; Alejandro Vazquez-Martin; Sílvia Cufí; Begoña Martin-Castillo; Vicente Micol; Jorge Joven; Antonio Segura-Carretero; Javier A Menendez
Journal:  Aging (Albany NY)       Date:  2012-07       Impact factor: 5.682
View more
  25 in total

1.  HIF-1α Inhibition Improves Anti-Tumor Immunity and Promotes the Efficacy of Stereotactic Ablative Radiotherapy (SABR).

Authors:  Chang W Song; Hyunkyung Kim; Haeun Cho; Mi-Sook Kim; Sun-Ha Paek; Heon-Joo Park; Robert J Griffin; Stephanie Terezakis; Lawrence Chinsoo Cho
Journal:  Cancers (Basel)       Date:  2022-07-04       Impact factor: 6.575

Review 2.  Targeting of the tumor immune microenvironment by metformin.

Authors:  Zihong Wu; Caidie Zhang; Masoud Najafi
Journal:  J Cell Commun Signal       Date:  2021-10-05       Impact factor: 5.908

Review 3.  Metformin, Microbiome and Protection Against Colorectal Cancer.

Authors:  Georgina R Jones; Mark P Molloy
Journal:  Dig Dis Sci       Date:  2020-06-12       Impact factor: 3.199

Review 4.  Repurposing metformin for the treatment of gastrointestinal cancer.

Authors:  Ademar Dantas Cunha Júnior; Arinilda Campos Bragagnoli; Felipe Osório Costa; José Barreto Campello Carvalheira
Journal:  World J Gastroenterol       Date:  2021-05-07       Impact factor: 5.742

Review 5.  Metformin: Sentinel of the Epigenetic Landscapes That Underlie Cell Fate and Identity.

Authors:  Javier A Menendez
Journal:  Biomolecules       Date:  2020-05-18

Review 6.  Drug delivery systems as immunomodulators for therapy of infectious disease: Relevance to COVID-19.

Authors:  Danielle Brain; Alex Plant-Hately; Bethany Heaton; Usman Arshad; Christopher David; Christian Hedrich; Andrew Owen; Neill J Liptrott
Journal:  Adv Drug Deliv Rev       Date:  2021-06-25       Impact factor: 17.873

7.  Programmed Death-Ligand 1 (PD-L1) Expression Is Induced by Insulin in Pancreatic Ductal Adenocarcinoma Cells Pointing to Its Role in Immune Checkpoint Control.

Authors:  Steffen M Heckl; Franziska Mau; Anke Senftleben; Tina Daunke; Silje Beckinger; Samir Abdullazade; Stefan Schreiber; Christoph Röcken; Susanne Sebens; Heiner Schäfer
Journal:  Med Sci (Basel)       Date:  2021-06-25

Review 8.  Manipulation of Metabolic Pathways and Its Consequences for Anti-Tumor Immunity: A Clinical Perspective.

Authors:  Huang-Yu Yang; Chao-Yi Wu; Jonathan D Powell; Kun-Lin Lu
Journal:  Int J Mol Sci       Date:  2020-06-04       Impact factor: 5.923

9.  Metformin and SARS-CoV-2: mechanistic lessons on air pollution to weather the cytokine/thrombotic storm in COVID-19.

Authors:  Javier A Menendez
Journal:  Aging (Albany NY)       Date:  2020-05-27       Impact factor: 5.682

10.  NCOA5 deficiency promotes a unique liver protumorigenic microenvironment through p21WAF1/CIP1 overexpression, which is reversed by metformin.

Authors:  Mark Williams; Xinhui Liu; Yueqi Zhang; Jake Reske; Devika Bahal; Trevor G Gohl; Daniel Hollern; Elliot Ensink; Matti Kiupel; Rongcheng Luo; Rupali Das; Hua Xiao
Journal:  Oncogene       Date:  2020-03-20       Impact factor: 9.867
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.